Synergistic IRAK4 Degrader Combinations for Enhanced MYD88-Mutant B-Cell Lymphoma Treatment

This inventive concept integrates IRAK4 degraders with distinct technologies, such as blockchain, AI, and IoT, to create a more powerful system for treating MYD88-mutant B-cell lymphomas, offering enhanced treatment efficacy and personalized care.

The original patent relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders. However, these methods have limitations in terms of treatment efficacy and patient data management. The present inventive concept addresses these limitations by combining IRAK4 degraders with advanced technologies to create a more comprehensive and effective treatment system.

The inventive concept involves integrating IRAK4 degraders with blockchain-based patient data management modules, machine learning algorithms for personalized dosing schedules, immunomodulatory agents selected based on genetic profiles, and wearable devices for real-time treatment monitoring. This synergistic combination enables secure and transparent data sharing, optimized treatment regimens, and enhanced patient outcomes.

The new claims introduce the novel concept of combining IRAK4 degraders with blockchain, AI, and IoT technologies, which is not obvious from the original patent. This integration provides a significant improvement in treatment efficacy and patient care, distinguishing the inventive concept from the original patent.

Alternative embodiments of the inventive concept could include integrating IRAK4 degraders with other emerging technologies, such as nanotechnology or gene editing, to further enhance treatment outcomes. Variations of the concept could also involve using different types of immunomodulatory agents or alternative data analytics platforms.

The inventive concept has significant commercial potential in the oncology market, particularly in the treatment of MYD88-mutant B-cell lymphomas. The integration of advanced technologies with IRAK4 degraders could lead to the development of more effective and personalized treatment options, addressing a significant unmet medical need.